1. Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification

   • Matthew Fabbro
   • Kirah Hahn
   • James F. O’Mahony

   Systematic Review Open access 30 August 2022 Pages: 773 - 786

   

2. The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis

   • Carina Østervig Andersen
   • Helena Travis
   • Emmelie Ploug Jørgensen

   Systematic Review Open access 22 August 2022 Pages: 787 - 797

   

3. Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis

   • Keith B. Allen
   • James E. Alexander
   • Susan Gabriel

   Original Research Article Open access 28 February 2022 Pages: 799 - 809

   

4. Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

   • David Elsea
   • Lin Fan
   • Dominic Muston

   Original Research Article Open access 29 August 2022 Pages: 811 - 822

   

5. An EQ-5D-5L Value Set for Belgium

   • Nicolas Bouckaert
   • Irina Cleemput
   • Sophie Gerkens

   Original Research Article Open access 04 August 2022 Pages: 823 - 836

   

6. Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia

   • Fabio Gil
   • Fabian Juliao-Baños
   • Juan Manuel Reyes

   Original Research Article Open access 09 August 2022 Pages: 837 - 846

   

7. What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care

   • Megan Dale
   • Sarah F Bell
   • Grace Carolan-Rees

   Original Research Article Open access 06 September 2022 Pages: 847 - 857

   

8. Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

   • Moogeh Baharnoori
   • Virender Bhan
   • Daniel Grima

   Original Research Article Open access 15 September 2022 Pages: 859 - 870

   

9. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

   • Andrew Blauvelt
   • Nianwen Shi
   • Mwangi J. Murage

   Original Research Article Open access 26 September 2022 Pages: 871 - 880

   

10. Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin

    • Holly Cranmer
    • David Trueman
    • Tanja Podkonjak

    Original Research Article Open access 04 September 2022 Pages: 881 - 892

    

11. Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates

    • Rachel Milstein Breslau
    • Joshua T. Cohen
    • Peter J. Neumann

    Research Letter Open access 23 July 2022 Pages: 893 - 895

12. Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis

    • Keith B. Allen
    • James E. Alexander
    • Susan Gabriel

    Correction Open access 27 September 2022 Pages: 897 - 897

13. Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

    • David Elsea
    • Lin Fan
    • Dominic Muston

    Correction Open access 15 September 2022 Pages: 899 - 899